Patient and Medical Community Engagement

At ProQR, we aim to develop best-in-class therapies in the most efficient manner as well as to improve patient care through awareness, education, and advancing the understanding of these conditions. From our beginnings, our approach is to integrate the patient voice at every step along the way as we develop our medicines. We act with a sense of purpose and urgency to ensure everything we do is in the interest of patients. This makes us ProQRians.

Although ProQR is still in the early stages of our development programs for cystic fibrosis (CF), Leber’s congenital amaurosis Type 10 (LCA10), and dystrophic epidermolysis bullosa (DEB), we strongly believe that this patient-centric strategy is crucial to our success, and so we established the Patient and Medical Community Engagement (PMCE) team. This dedicated team functions to listen to and represent the patient voice internally and to collaborate with the communities that we serve.

Learn more about our progress in our development programs: For questions, please contact us via the contact form below or email
At ProQR we always think about the patients and how to make their lives better. We call this our patient-centric drug development strategy. We listen to and work together with the communities we serve and use groundbreaking science to develop medicines that will transform the lives of patients with severe genetic disorders. - Daniel de Boer, CEO ProQR Therapeutics

ProQR in the Community

Members of Team ProQR talking about their motivation to participate during the Skate4air 2016 event to support fundraising efforts for further research in CF.

News updates for the community

QR-010 Development Program Update
On November 4th 2017, ProQR announced results of a QR-010 Phase 1b clinical trial with CF patients that are homozygous- or carrying two copies- for the F508del mutation.
Read update

Language: CZ | DE | EN | FR | NL
Acting in the interest of patients
In this interview from October 2016, Daniel de Boer, Chief Executive Officer and Noreen Henig M.D., Chief Development Officer, tell us more about the company and the important milestone of first clinical data in CF patients.
Read interview

Language: CZ | DE | EN | DK | ES | FR | IT | NL

ProQR’s Guiding Principles

The Guiding Principles for ProQR’s patient-centric approach are:

  • We are committed to the communities we serve and emphasize a patient-centric approach in everything we do.
  • We value patients as experts and strive to integrate real-life insights into our decision-making throughout the drug development process.
  • We act with a sense of urgency and purpose in the interest of patients.
  • We believe in early and consistent engagement and being transparent with the patient community.

Get in touch

You are now leaving ProQR Therapeutics

ProQR Therapeutics provides links to web sites of other organizations in order to provide visitors with certain information. A link does not constitute an endorsement of content, viewpoint, policies, products or services of that web site. Once you link to another web site not maintained by ProQR Therapeutics, you are subject to the terms and conditions of that web site, including but not limited to its privacy policy.

You will be redirected to

Click the link above to continue or CANCEL